Safety and Tolerability of Bimagrumab in Sporadic Inclusion Body Myositis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-Term Safety and Tolerability of Bimagrumab (BYM338) in Sporadic Inclusion Body Myositis
Neurology 2020 Oct 06;95(14)e1971-e1978, K Sivakumar, TI Cochrane, B Sloth, H Ashar, D Laurent, LB Tankó, AA AmatoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.